검색
NewAmsterdam Pharma Company NV
NAMS관심 목록에 추가
34.734USD
+0.845+2.49%
시장 운영 시간 （ET）시세는 15분 지연됩니다
4.05B시가총액
손실P/E TTM
자세한 내용은 NewAmsterdam Pharma Company NV 회사
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV 정보
종목 코드 NAMS
회사 이름NewAmsterdam Pharma Company NV
상장일Nov 23, 2022
CEODavidson (Michael Harvey)
직원 수68
유형Ordinary Share
회계 연도 종료Nov 23
주소Gooimeer 2-35
도시NAARDEN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Netherlands
우편 번호1411 DC
전화31352062971
웹사이트https://ir.newamsterdampharma.com/
종목 코드 NAMS
상장일Nov 23, 2022
CEODavidson (Michael Harvey)
NewAmsterdam Pharma Company NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
자주 묻는 질문
NewAmsterdam Pharma Company NV의 상위 5대 주주는 누구인가요?
NewAmsterdam Pharma Company NV의 상위 5대 주주는 다음과 같습니다: Mr. John W. Smither
NewAmsterdam Pharma Company NV(NAMS)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, NewAmsterdam Pharma Company NV의 주식을 보유한 기관은 총 366곳이며, 이들이 보유한 주식의 총 가치는 약 128.70M로 전체 발행 주식의 110.09%를 차지합니다. 이는 2025Q4 대비 2432976.00 증가한 수치입니다.